These findings suggest that the prognostic value of adiponectin levels in CKD may be significantly modulated by demographic and clinical factors, highlighting the importance of considering patient-specific characteristics when evaluating mortality risk. This evidence concerns the gene ADIPOQ and chronic kidney disease.